Global Induced Pluripotent Stem Cells Production Market Insights Forecasts to 2033

• The Global Induced Pluripotent Stem Cells Production Market Size was Valued at USD 1.25 Billion in 2023
• The Market Size is Growing at a CAGR of 9.68% from 2023 to 2033
• The Worldwide Induced Pluripotent Stem Cells Production Market Size is Expected to Reach USD 3.15 Billion by 2033
• Asia-Pacific is Expected to Grow the fastest during the forecast period.

 

Get more details on this report -

Request Free Sample PDF

 

 

The Global Induced Pluripotent Stem Cells Production Market Size is Anticipated to Exceed USD 3.15 Billion by 2033, Growing at a CAGR of 9.68% from 2023 to 2033.

 

Market Overview

Induced pluripotent stem (iPS) cells are a type of pluripotent stem cell derived from adult somatic cells. They are differentiated cells that have been experimentally reprogrammed to an embryonic stem (ES) cell-like state. Induced pluripotent stem cells (iPSCs) can be used to overcome limitations associated with primary cells. The diverse cell types differentiated from iPSCs can be utilized for toxicity testing, evaluation of new drugs, and in vitro developmental processes. This helps eliminate immune system rejection, which can sometimes occur when the body's immune system identifies implanted cells or tissues as unknown bodies and attacks them. The use of iPSCs for preclinical tests might cut the cost associated with providing animal models, which ultimately decreases the overall costs of the clinical trials. The generation of induced pluripotent stem cells (iPSCs) has revolutionized the field of regenerative medicine by providing researchers with a unique tool to derive disease-specific stem cells for study. Using an Epi reprogramming vector (c-Myc-free and non-integrating) and CRISPR technology, iPSCs produced from urine-derived cells from a patient with spinal muscular atrophy were utilized to fix the disease-causing mutation at the iPSC level.

 

Report Coverage

This research report categorizes the market for the global induced pluripotent stem cells production market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global induced pluripotent stem cells production market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global induced pluripotent stem cells production market.

 

Driving Factors

Cell therapy, immunotherapy, somatic cell induced pluripotent stem cells, primary tumors, and people with genetic predispositions to cancer have all demonstrated remarkable promise for cancer modeling, tumor progression knowledge, and cell therapy. The growing prevalence of cancer surges the need for induced pluripotent stem cells production for studying tumorigenesis. iPSCs offer the potential for personalized cell-based therapies in the field of regenerative medicine. iPSC-derived cells are widely used for modeling human development and diseases, performing high-throughput drug screening, and developing autologous and allogeneic cell therapies, among other applications. Further, the increased applications in neural drug discovery and development augment the market demand for induced pluripotent stem cells production. The increased interest in personalized medicine and surge in healthcare expenditure leveraging the market growth for induced pluripotent stem cells production.

 

Restraining Factors

The requirement to comply with all regulations pertaining to biomedical research and the high cost associated with stem cell therapies are restraining the market growth. Further, the availability of alternatives for tumor treatment is hampering the global induced pluripotent stem cells production market.

 

Market Segmentation

The global induced pluripotent stem cells production market share is classified into process, product & services, application, and end-use.

 

• The manual iPSC production process segment is expected to hold the largest share of the global induced pluripotent stem cells production market during the forecast period.   

Based on the process, the global induced pluripotent stem cells production market is categorized into manual iPSC production process and automated iPSC production process. Among these, the manual IPSC production process segment is expected to hold the largest share of the global induced pluripotent stem cells production market during the forecast period. The manual iPSC production includes the introduction of genes and transcription factors into the growing somatic cells followed by reprogramming, colony selection, iPSC expansion, and iPSC passaging. It is a flexible and precise manufacturing process that can cater to diverse experimental needs.

 

• The consumables & kits segment dominated the market with the largest revenue share in 2023.

Based on the product & services, the global induced pluripotent stem cells production market is categorized into products, consumables & kits, instruments/ devices, automated platforms and service. Among these, the consumables & kits segment dominated the market with the largest revenue share in 2023. The variety of induced pluripotent stem cell (iPSC) kits, including/ such as reprogramming, differentiation, and generation kits are used by the end-users as per desired application with the selection of media and other consumables by key market players. The adoption of iPSC technology for regenerative medicine and drug discovery are driving the market in the consumables & kits segment.

 

• The drug development & discovery segment accounted for the largest revenue share of the global induced pluripotent stem cells production market in 2023.

Based on the application, the global induced pluripotent stem cells production market is categorized into drug development & discovery, regenerative medicine, toxicology studies, and others. Among these, the drug development & discovery segment accounted for the largest revenue share of the global induced pluripotent stem cells production market in 2023. Induced pluripotent stem cells are widely used for the development of innovative treatment plans. The rising technological advancements for more targeted and efficient drug development processes for effective therapy among growing cancer and other chronic diseased patients are driving the market growth.  

 

• The research & academic institutes segment dominated the global induced pluripotent stem cells production market in 2023.

Based on the end-use, the global induced pluripotent stem cells production market is categorized into pharmaceutical & biotechnology companies, research & academic institutes, and contract research organizations. Among these, the research & academic institutes segment dominated global induced pluripotent stem cells production market in 2023. iPSCs have wide applications and are thus being utilized in many research as well as clinical studies for regenerative studies which provides favorable prospects for translating this technology into clinical use. The growing interest and investments in stem cell therapy and research are propelling the market in the research & academic institutes segment.

 

Regional Segment Analysis of the Global Induced Pluripotent Stem Cells Production Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global induced pluripotent stem cells production market over the predicted timeframe.

 

Get more details on this report -

Request Free Sample PDF

 

North America is projected to hold the largest share of the global induced pluripotent stem cells production market over the forecast period. The robust infrastructure for biotechnology R&D, and significant investment in iPSC research are driving the market in the region. The growing adoption of highly advanced technologies and systems in drug development, toxicity testing, and disease modeling, coupled with the growing acceptance of stem cell therapies are significantly contributing to market growth. Further, the strong regulatory framework, and strategic collaboration among key market players in the region driving the market.  

 

Asia Pacific is expected to grow at the fastest CAGR growth of the global induced pluripotent stem cells production market during the forecast period. The increasing research activities over stem cell therapies in the region with the growing biotechnology sector driving the market. The better investment and rising prevalence of chronic diseases act as drivers for the induced pluripotent stem cells (iPSCs) market. Further, a wide range of clinical applications of induced pluripotent stem cells and emerging technological advancements of iPSCs are contributed to drive the market.   

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global induced pluripotent stem cells production market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Cynata Therapeutics
• Evotec SE
• Axol Biosciences Ltd.
• Lonza
• FUJIFILM Cellular Dynamics, Inc.
• Ncardia
• REPROCELLS, Inc.
• Thermo Fisher Scientific, Inc.
• Fate Therapeutics
• Hitachi, Ltd.
• Merck KGaA
• StemCellsFactory III
• Applied StemCells, Inc.
• Pluricell Biotech
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments

• In November 2022, Prepaire announced a partnership with Ncardia to accelerate plans to discover new drugs and repurpose existing libraries. The new effort would launch efforts to design iPSCs by reprogramming adult cells (e.g., skin cells, blood cells) to an embryonic stem cell-like state, with the potential to become any cell type of the human body.

 

• In September 2021, Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global induced pluripotent stem cells production market based on the below-mentioned segments: 

 

Global Induced Pluripotent Stem Cells Production Market, By Process

• Manual iPSC Production Process
• Automated iPSC Production Process

 

Global Induced Pluripotent Stem Cells Production Market, By Product & Services

• Products
• Consumables & Kits
• Instruments/ Devices
• Automated Platforms
• Service

 

Global Induced Pluripotent Stem Cells Production Market, By Application

• Drug Development & Discovery
• Regenerative Medicine
• Toxicology Studies
• Others

 

Global Induced Pluripotent Stem Cells Production Market, By End-Use

• Pharmaceutical & Biotechnology Companies
• Research & Academic Institutes
• Contract Research Organizations

 

Global Induced Pluripotent Stem Cells Production Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa